Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in 4D MOLECULAR THERAPEUTICS IN
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC previously held 0 shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $0 as of 2025-Q1.
Final Value
$0
Final Shares
0
Total Value Change
-$1M
Total Shares Change
-47,652
Other major holders of FDMT: VIKING GLOBAL INVESTORS LP, RA CAPITAL MANAGEMENT, L.P., BlackRock Finance, Inc.
Exited |
| 0 |
-100.0% |
| $0 |
| 0.0% |
| $3.63 |
0 |
| 2024-Q4 | Increased | 44,324 | +7.1% | $246,884 | 0.0% | $5.30 | 25 |
| 2024-Q3 | Decreased | 41,399 | -13.1% | $447,523 | 0.0% | $10.83 | 0 |
| 2024-Q2 | Increased | 47,652 | +48.5% | $1M | 0.0% | $20.99 | 34 |